The content on this site is intended for healthcare professionals only
ASCO 2022: Highlights and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
6 Jun 2022
Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer wi...
Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San ...
6 Jun 2022
ASCO 2022: Breast cancer highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
6 Jun 2022
Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer
Dr Etienne Brain - Institut Curie, Paris, France
6 Jun 2022
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03
Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA
5 Jun 2022
Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 exp...
Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre, Manhattan, USA
5 Jun 2022
Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic b...
Dr Jane Lowe Meisel- Winship Cancer Institute of Emory University, Georgia, USA
5 Jun 2022
Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast can...
Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA
5 Jun 2022
Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone rece...
Dr Hope Rugo - University of California San Francisco, San Francisco, USA
4 Jun 2022
Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancer
Dr Jane Lowe Meisel - Winship Cancer Institute of Emory University, Georgia, USA
4 Jun 2022
Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer
Dr Hope Rugo - University of California San Francisco, San Francisco, USA
4 Jun 2022
Cancer Services Delivery: Focus on India
Dr Soumitra Datta - Tata Medical Center, Kolkata, India
26 May 2022